Did you read the article?
THIS IS A DIRECT cut and paste from your article
"Neither sorafenib nor SIR-Spheres Y-90 resin microspheres produced a statistically significant difference in Overall Survival (OS) of the patients we studied," said Prof. Vilgrain. "Despite 26.6% of patients in the SIRT arm not receiving SIR-Spheres per protocol, the primary endpoint of Overall Survival by intention-to-treat [ITT] was not significantly different (median 8.0 vs. 9.9 months; p=0.18). Moreover, if we look at the patients who received SIR-Spheres or sorafenib according to the SARAH protocol, median OS was identical (9.9 vs. 9.9 months; p=0.92)."
Oh dear the product is ....
- Forums
- ASX - By Stock
- SRX
- Ann: Ceasing to be a substantial holder from HHL
Ann: Ceasing to be a substantial holder from HHL, page-10
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SRX (ASX) to my watchlist
|
|||||
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M |
Open | High | Low | Value | Volume |
17.5¢ | 18.0¢ | 17.5¢ | $401.1K | 2.230M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 5285064 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 2965318 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 7755 | 0.180 |
12 | 4965064 | 0.175 |
3 | 572000 | 0.170 |
4 | 94458 | 0.165 |
3 | 166150 | 0.160 |
Price($) | Vol. | No. |
---|---|---|
0.175 | 7756 | 1 |
0.180 | 3422484 | 15 |
0.185 | 248731 | 3 |
0.190 | 87847 | 4 |
0.195 | 500000 | 1 |
Last trade - 14.58pm 23/07/2024 (20 minute delay) ? |
Featured News
SRX (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online